Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cash & Equivalents (2016 - 2026)

Catalyst Pharmaceuticals filings provide 17 years of Cash & Equivalents readings, the most recent being $755.9 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 30.17% to $755.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $755.9 million, a 30.17% increase, with the full-year FY2025 number at $709.2 million, up 37.02% from a year prior.
  • Cash & Equivalents hit $755.9 million in Q1 2026 for Catalyst Pharmaceuticals, up from $709.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $755.9 million in Q1 2026 to a low of $121.0 million in Q3 2023.
  • Median Cash & Equivalents over the past 5 years was $310.4 million (2024), compared with a mean of $386.1 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 53.87% in 2023 and later soared 276.03% in 2024.
  • Catalyst Pharmaceuticals' Cash & Equivalents stood at $298.4 million in 2022, then crashed by 53.87% to $137.6 million in 2023, then soared by 276.03% to $517.6 million in 2024, then skyrocketed by 37.02% to $709.2 million in 2025, then grew by 6.58% to $755.9 million in 2026.
  • The last three reported values for Cash & Equivalents were $755.9 million (Q1 2026), $709.2 million (Q4 2025), and $689.9 million (Q3 2025) per Business Quant data.